Despite 'lackluster' 2022, PwC remains 'bullish' on pharma M&A in 2023
While 2022 was shaping up to be a busy year for M&A, PwC recorded an overall “lackluster” amount of activity, with both deal size and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
